Long-term safety study of idecabtagene vicleucel for multiple myeloma in Korea
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study follows up on Korean adults with multiple myeloma who received the CAR T-cell therapy idecabtagene vicleucel (also called Ide-cel) in a previous trial (KarMMa-9) and did not have an optimal response after a stem cell transplant. The goal is to monitor long-term safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years old or older
- You are Korean and have newly diagnosed multiple myeloma
- You received idecabtagene vicleucel (Ide-cel) in the KarMMa-9 trial after a stem cell transplant that didn't work as well as hoped
- You agree to take part in long-term follow-up in Korea
- You must not have disagreed with long-term follow-up in the previous trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry study will follow people who have received the CAR T-cell therapy equecabtagene autoleucel to monitor their long-term health and outcomes. It is open to those who completed or withdrew from an earlier study of this treatment.
This trial provides access to a CAR T-cell therapy (ide-cel) that was made for you but didn't meet commercial release standards. It's an expanded access program for patients who have no other options and are stable enough to receive the treatment.
This trial tests a one-time cell therapy called ciltacabtagene autoleucel (a CAR-T treatment) in people who have newly diagnosed multiple myeloma and are not eligible for a stem cell transplant. It aims to see if this treatment is safe and effective as an early therapy.
This study tests a new CAR-T cell therapy called Eque-cel for people with multiple myeloma that no longer responds to lenalidomide. It aims to see if this treatment can help control the disease after 1-2 prior therapies.
This early-stage study tests whether giving a drug called iberdomide before collecting cells for CAR-T therapy can make the cells healthier and more effective in treating multiple myeloma that has come back or hasn't responded to previous treatments.
This trial tests a combination of three drugs (elotuzumab, iberdomide, and dexamethasone) for multiple myeloma that has come back after treatment with a type of CAR T-cell therapy called ide-cel. It aims to see if this new combination can help people who have already tried several other treatments.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.